Eli Lilly has once again put its payroll in the deep freeze. For the third year in a row, the U.S.-based drugmaker says most employees won't see salary increases because of patent-cliff losses, <em>The Wall Street Journal</em> reports. And Lilly is cutting cash bonuses, too.
written on 25.03.2014